Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 987 (LINC00987)
- Target
- LINC00987
- Molecular classification
- Long non-coding RNA, Non-protein coding RNA, lincRNA
01
Overview
Long intergenic non-protein coding RNA 987 (LINC00987) is a long non-coding RNA found on chromosome 12p13.31. It does not encode protein but functions as a regulatory RNA, especially implicated in cancer biology. In acute myeloid leukemia, LINC00987 promotes Adriamycin resistance by acting as a competing endogenous RNA for miR-4458, influencing levels of HMGA2 and drug resistance proteins (P-GP, BCRP), and its elevated expression is associated with poor prognosis. LINC00987 may also serve as a tumor suppressor and immune microenvironment biomarker in several other cancers. Therapeutic targeting of LINC00987 is theoretical, as no drugs currently directly target this lncRNA, but it significantly affects drug response pathways and prognosis in malignancies[1][2][3][4].
- Other names
- LINC00987long intergenic non-protein coding RNA 987
02
Mechanism of action
Modulates drug (Adriamycin) resistance by functioning as a ceRNA for miR-4458, thereby indirectly regulating expression of HMGA2 and drug resistance proteins such as P-GP and BCRP[2]
03
Biological functions
Competing endogenous RNA (ceRNA) activity, specifically sponging of miRNAs such as miR-4458[2]Regulation of drug resistance (notably Adriamycin resistance in acute myeloid leukemia cells)[2]Regulation of cellular proliferation and apoptosis (AML context)[2]Potential immune regulation roles and tumor microenvironment modulation (pan-cancer evidence)[4]
04
Disease associations
Cancer (with specific evidence in acute myeloid leukemia drug resistance and prognosis)[2][4]Potential biomarker or functional influence in a range of other cancers, including prostate, liver, lung, melanoma, and others (pan-cancer studies)[4]
05
Safety considerations
None specifically reported. As a non-coding RNA, therapeutic modulation would require careful off-target and delivery system evaluation, but such information is currently lacking in the literature[2][4]
06
Interacting drugs
Adriamycin (doxorubicin), via influencing chemoresistance in AML cells[2]
07
Biomarkers
Expression levels of LINC00987 as a prognostic biomarker in AML and potentially a biomarker for immune microenvironment and patient stratification in various cancers[2][4]LINC00987/A2M axis as a biomarker for immune contexture in tumor tissues[4]
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 987 (LINC00987).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 987 (LINC00987).